CBD Studies Database - Bioavailability
Did you know that the amount of CBD that is entering your system is dependent on a multitude of factors aside from what is written on the container? If you take it orally, topically, sublingually, or with food, the amount of CBD you are receiving may vary greatly. This is known as bioavailability, a subcategory of absorption that researchers are analyzing to better understand the variables that impact the absorption of CBD.
A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray
This study’s purpose was to assess the effect of food on the single-dose bioavailability of delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) spray, an endocannabinoid system modulator, when administered to healthy male subjects.
This study aims to establish the CBD dose-exposure relationship and to evaluate the effects of dosage forms, food, and doses on CBD absorption.
Summary: This article provides a critical appraisal of the available evidence concerning clinical exposure to orally administered cannabidiol (CBD), with special reference to factors affecting gastrointestinal absorption, presystemic elimination, and susceptibility to metabolic drug interactions.
Summary: This review identifies issues compromising current delivery of solid-state CBD, and how advanced pharmaceutical development strategies can enable CBD to realize the full potential as a successful therapeutic agent.
Summary: This study explored the utility of an advanced lipid based Self-Emulsifying Drug Delivery System termed Advanced Pro-NanoLiposphere (PNL) pre-concentrate on CBD and THC oral bioavailability.
Summary: This study compares the bioavailability of THC and CBD from the PTL401 capsule with similar doses from a marketed reference oromucosal spray (Sativex®).
Summary: This study’s aim was to test the hypothesis that pre-digested lipid formulations (oleic acid, linoleic acid, oleic acid with 2-oleoylglycerol, oleic acid with 2-oleoylglycerol and oleic acid with glycerol) could reduce variability and increase the extent of the intestinal lymphatic transport and oral bioavailability of CBD.